Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Smith & Nephew Plc
  6. Summary
    SN.   GB0009223206

SMITH & NEPHEW PLC

(SN.)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
1257.5(c) 1243.5(c) 1253(c) 1274(c) 1277(c) Last
895 823 1 742 931 959 283 1 099 112 1 908 386 Volume
+0.16% -1.11% +0.76% +1.68% +0.24% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 5 360 M - -
Net income 2021 469 M - -
Net Debt 2021 1 973 M - -
P/E ratio 2021 34,0x
Yield 2021 2,02%
Sales 2022 5 719 M - -
Net income 2022 697 M - -
Net Debt 2022 1 541 M - -
P/E ratio 2022 22,3x
Yield 2022 2,28%
Capitalization 15 417 M 15 431 M -
EV / Sales 2021 3,24x
EV / Sales 2022 2,97x
Nbr of Employees 18 000
Free-Float 99,1%
More Financials
Company
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The... 
More about the company
Ratings of Smith & Nephew Plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about SMITH & NEPHEW PLC
10/15SMITH & NEPHEW : Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act ..
PU
10/11SMITH & NEPHEW : Timing of Smith+Nephew Third Quarter 2021 Trading Report
AQ
10/08SMITH & NEPHEW : Timing of Smith+Nephew Third Quarter 2021 Trading Report - Form 6-K
PU
10/08SMITH & NEPHEW : Timing of Smith+Nephew Third Quarter 2021 Trading Report
PU
10/05SMITH & NEPHEW : Barclays Cuts Smith & Nephew PT, Keeps Overweight Rating
MT
10/04SMITH & NEPHEW : Citigroup Trims Smith & Nephew PT, Maintains Neutral Rating
MT
10/01WALL STREET STOCK EXCHANGE : Autumn cold snap
10/01SMITH & NEPHEW : Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act ..
PU
10/01ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot,..
09/30SMITH & NEPHEW : Barclays Trims Smith & Nephew PT, Keeps Overweight Rating
MT
09/30SMITH & NEPHEW PLC : Ex-dividend day for interim dividend
FA
09/24SMITH & NEPHEW : Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act ..
PU
09/21SMITH & NEPHEW : Investor presentation July - September 2021
PU
09/16European ADRs Move Lower in Thursday Trading
MT
09/16SMITH & NEPHEW : Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act ..
PU
More news
News in other languages on SMITH & NEPHEW PLC
10/01AVIS D'ANALYSTES DU JOUR : Vivendi, UMG, Sartorius Stedim Biotech, Nokia, BMW, Sulzer, Wiz..
09/16Les ADR européens en baisse jeudi
08/31De nouvelles données soulignent les avantages matériels de la technologie Oxinium Dh et..
08/27Les ADR européens progressent de près de 1% vendredi matin
08/23Les ADR européens en hausse lundi
More news
Analyst Recommendations on SMITH & NEPHEW PLC
More recommendations
Chart SMITH & NEPHEW PLC
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 17,56 $
Average target price 21,96 $
Spread / Average Target 25,1%
EPS Revisions
Managers and Directors
Roland D. Diggelmann Chief Executive Officer & Non-Executive Director
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Roberto Quarta Chairman
Vasant Padmanabhan President-Research & Development
Catheryn O'Rourke Chief Legal & Compliance Officer
Sector and Competitors